

# Adamantios Mamais

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5051164/publications.pdf>

Version: 2024-02-01

33  
papers

1,755  
citations

279798

23  
h-index

377865

34  
g-index

38  
all docs

38  
docs citations

38  
times ranked

2403  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dysregulation of glucose metabolism is an early event in sporadic Parkinson's disease. <i>Neurobiology of Aging</i> , 2014, 35, 1111-1115.	3.1	174
2	LRRK2 links genetic and sporadic Parkinson's disease. <i>Biochemical Society Transactions</i> , 2019, 47, 651-661.	3.4	148
3	LRRK2 mediates tubulation and vesicle sorting from lysosomes. <i>Science Advances</i> , 2020, 6, .	10.3	140
4	Inhibition of LRRK2 kinase activity stimulates macroautophagy. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2013, 1833, 2900-2910.	4.1	124
5	Phosphorylation of LRRK2 by casein kinase 1 $\pm$ regulates trans-Golgi clustering via differential interaction with ARHGEF7. <i>Nature Communications</i> , 2014, 5, 5827.	12.8	90
6	Pathogenic Parkinson's disease mutations across the functional domains of LRRK2 alter the autophagic/lysosomal response to starvation. <i>Biochemical and Biophysical Research Communications</i> , 2013, 441, 862-866.	2.1	79
7	Regulation of V(D)J recombination by nucleosome positioning at recombination signal sequences. <i>EMBO Journal</i> , 2003, 22, 5197-5207.	7.8	69
8	mTOR independent regulation of macroautophagy by Leucine Rich Repeat Kinase 2 via Beclin-1. <i>Scientific Reports</i> , 2016, 6, 35106.	3.3	69
9	Globular glial tauopathies (GGT) presenting with motor neuron disease or frontotemporal dementia: an emerging group of 4-repeat tauopathies. <i>Acta Neuropathologica</i> , 2011, 122, 415-428.	7.7	67
10	Detection of endogenous S1292 LRRK2 autophosphorylation in mouse tissue as a readout for kinase activity. <i>Npj Parkinson's Disease</i> , 2018, 4, 13.	5.3	59
11	Transcriptome analysis of LRRK2 knock-out microglia cells reveals alterations of inflammatory- and oxidative stress-related pathways upon treatment with $\pm$ -synuclein fibrils. <i>Neurobiology of Disease</i> , 2019, 129, 67-78.	4.4	53
12	Proteomic analysis reveals co-ordinated alterations in protein synthesis and degradation pathways in LRRK2 knockout mice. <i>Human Molecular Genetics</i> , 2018, 27, 3257-3271.	2.9	52
13	LRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	49
14	The Parkinson's Disease Protein LRRK2 Interacts with the GARP Complex to Promote Retrograde Transport to the trans-Golgi Network. <i>Cell Reports</i> , 2020, 31, 107614.	6.4	49
15	Mutations in LRRK2 linked to Parkinson disease sequester Rab8a to damaged lysosomes and regulate transferrin-mediated iron uptake in microglia. <i>PLoS Biology</i> , 2021, 19, e3001480.	5.6	48
16	Fine-Mapping, Gene Expression and Splicing Analysis of the Disease Associated LRRK2 Locus. <i>PLoS ONE</i> , 2013, 8, e70724.	2.5	45
17	A Parkinson's disease gene regulatory network identifies the signaling protein RGS2 as a modulator of LRRK2 activity and neuronal toxicity. <i>Human Molecular Genetics</i> , 2014, 23, 4887-4905.	2.9	45
18	Divergent $\pm$ -synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases. <i>Neurobiology of Disease</i> , 2013, 58, 183-190.	4.4	44

#	ARTICLE	IF	CITATIONS
19	Hexokinases link DJ-1 to the PINK1/parkin pathway. <i>Molecular Neurodegeneration</i> , 2017, 12, 70.	10.8	40
20	Phosphorylation of 4E-BP1 in the Mammalian Brain Is Not Altered by LRRK2 Expression or Pathogenic Mutations. <i>PLoS ONE</i> , 2012, 7, e47784.	2.5	39
21	Arsenite Stress Down-regulates Phosphorylation and 14-3-3 Binding of Leucine-rich Repeat Kinase 2 (LRRK2), Promoting Self-association and Cellular Redistribution. <i>Journal of Biological Chemistry</i> , 2014, 289, 21386-21400.	3.4	38
22	Preclinical modeling of chronic inhibition of the Parkinson's disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo. <i>Molecular Neurodegeneration</i> , 2021, 16, 17.	10.8	29
23	Pathogenic LRRK2 Mutations Do Not Alter Gene Expression in Cell Model Systems or Human Brain Tissue. <i>PLoS ONE</i> , 2011, 6, e22489.	2.5	27
24	Sequential screening nominates the Parkinson's disease associated kinase LRRK2 as a regulator of Clathrin-mediated endocytosis. <i>Neurobiology of Disease</i> , 2020, 141, 104948.	4.4	27
25	Analysis of macroautophagy related proteins in G2019S LRRK2 Parkinson's disease brains with Lewy body pathology. <i>Brain Research</i> , 2018, 1701, 75-84.	2.2	25
26	Genetic analysis of neurodegenerative diseases in a pathology cohort. <i>Neurobiology of Aging</i> , 2019, 76, 214.e1-214.e9.	3.1	25
27	Acetylation increases access of remodelling complexes to their nucleosome targets to enhance initiation of V(D)J recombination. <i>Nucleic Acids Research</i> , 2007, 35, 6311-6321.	14.5	17
28	mTOR independent alteration in ULK1 Ser758 phosphorylation following chronic LRRK2 kinase inhibition. <i>Bioscience Reports</i> , 2018, 38, .	2.4	16
29	Relationship of p21-activated kinase (PAK) and filopodia to persistence and oncogenic transformation. <i>Journal of Cellular Physiology</i> , 2009, 220, 576-585.	4.1	13
30	GTP binding controls complex formation by the human ROCO protein MASL 1. <i>FEBS Journal</i> , 2014, 281, 261-274.	4.7	13
31	Differences in Stability, Activity and Mutation Effects Between Human and Mouse Leucine-Rich Repeat Kinase 2. <i>Neurochemical Research</i> , 2019, 44, 1446-1459.	3.3	7
32	Convergence of signalling pathways in innate immune responses and genetic forms of Parkinson's disease. <i>Neurobiology of Disease</i> , 2022, 169, 105721.	4.4	6
33	<sc>LRRK2</sc>: dropping (kinase) inhibitions and seeking an (immune) response. <i>Journal of Neurochemistry</i> , 2014, 129, 895-897.	3.9	4